Actualités et Activités de Cyclacel Pharmaceuticals
Dirigeants
Voir l'organigramme avec ses 7 principaux dirigeants
Biographies les plus recherchées chez Cyclacel Pharmaceuticals
- Wong Sing Ee, Chief Executive Officer and Executive Director
- Christopher Henney, Chairman of the Board
- Kenneth Ferguson, Director
Changements de dirigeants chez Cyclacel Pharmaceuticals
- Wong Sing Ee, a rejoint l'entreprise comme Chief Executive Officer and Executive Director (publié le 2 mars 2025).
- Kiu Cu Seng, a rejoint l'entreprise comme Executive Director, Secretary and Chief Financial Officer (publié le 2 mars 2025).
- Samuel Barker, Director, a quitté l'entreprise (publié le 2 mars 2025).
Créer une alerte
pour suivre les mouvements de dirigeants chez Cyclacel Pharmaceuticals.
Pharmacie
Cyclacel Pharmaceuticals a 1 834 concurrents dont Pfizer (Etats—Unis), Sanofi (France) et Eli Lilly (Etats—Unis).
Actualités en fusion/acquisition en Pharmacie.
- Imbria Pharmaceuticals vient d'annoncer une levée de fonds de 58 millions de dollars. (publié le 10 avril 2025).
- Clario a acquis NRx Pharmaceuticals (publié le 18 mars 2025).
- Knight Therapeutics has announced the acquisition of Paladin Labs (publié le 12 mars 2025).
Contacts en Pharmacie
Actualités
Derniers communiqués de presse par Cyclacel Pharmaceuticals
- Cyclacel Pharmaceuticals to Release First Quarter 2022 Financial Results | Cyclacel Pharmaceuticals, Inc.
- RSS News Feeds | Cyclacel Pharmaceuticals, Inc.
- Cyclacel Pharmaceuticals to Present at the October 2020 Lytham Partners Virtual Investor Growth Conference | Cyclacel Pharmaceuticals, Inc.
- Cyclacel Announces Fadraciclib Abstract Selected for Oral Presentation in the Late Breaking and Best Proffered Paper Session at the 32nd EORTC-NCI-AACR Symposium 2020 | Cyclacel Pharmaceuticals, Inc.
- Cyclacel Pharmaceuticals Reports Second Quarter 2020 Financial Results | Cyclacel Pharmaceuticals, Inc.
- Cyclacel Pharmaceuticals to Release Second Quarter 2020 Financial Results | Cyclacel Pharmaceuticals, Inc.
- Cyclacel’s Clinical Stage CDK2/9 Inhibitor Fadraciclib Targets Key Anti-Apoptotic and Oncogenic Pathways in Cancer | Cyclacel Pharmaceuticals, Inc.
- Cyclacel Pharmaceuticals Reports First Quarter 2020 Financial Results | Cyclacel Pharmaceuticals, Inc.
- Cyclacel Pharmaceuticals to Release First Quarter 2020 Financial Results | Cyclacel Pharmaceuticals, Inc.
- CYCLACEL ANNOUNCES PRICING OF $20 MILLION PUBLIC OFFERING | Cyclacel Pharmaceuticals, Inc.
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Cyclacel Pharmaceuticals
- Cyclacel Pharmaceuticals sur Wikipédia, Google News & Yahoo Finance en 1-click
- Cyclacel Pharmaceuticals sur LinkedIn, Twitter & YouTube en 1-click
